How is Australia responding to the pharmaceutical opioid problem?

Dr Gabrielle Campbell
image - Gabrielle Campbell 280 0

In the last twenty years there have been substantial increases in the use of pharmaceutical opioids in many countries, including Australia which has one of the highest levels of opioid utilisation globally 1. Almost 15 million opioid prescriptions were dispensed in 2015 and our use of high-potency opioids has also increased 2. One of the main drivers is the increased use of prescription opioids for chronic non-caner pain (CNCP) 3. In parallel to escalating use, opioid-related harms have also increased. Since 2000, there has been a shift in both hospitalisations due to opioid poisonings and opioid-related deaths, from predominantly heroin to pharmaceutical opioids4. Extra-medical use (defined as any use of a medication outside the formal medical system or inconsistent with a doctor's prescription5) is also relatively common; the most recent household survey indicates ‘non-medical use’ (the terminology used in this survey) was reported by 4.8% of the Australian population4.

A range of possible strategies to minimise unnecessary opioid exposure and adverse events were highlighted in the National Pharmaceutical Drug Misuse Framework for Action (2012-2015)6 including: coordinated medication management systems (prescription drug monitoring programmes (PDMPs); improvement of access to pain and addiction services; development of resources, and workforce development. To date, few of these strategies have been implemented. We summarise recent and emerging responses in Australia that aim to minimise harms from pharmaceutical opioids.

Regulatory responses aimed at reducing aberrant opioid prescribing and restricting opioid supply

Codeine rescheduling

In 2016, the most common analgesics used for ‘non-medical’ purposes by Australians were over-the-counter (OTC) codeine products4. There have been several attempts to reduce extra-medical use and harms from OTC codeine. In May 2010, OTC codeine products were up-scheduled from Schedule 2 (Pharmacy Medicine) to Schedule 3 (Pharmacist Only Medicine). This change, however, had no meaningful impact on codeine poisonings 7. They were subsequently up-scheduled again in February 2018 to Schedule 4 (Prescription-only medicines). The impacts of this decision remain to be seen 8.

Prescription drug monitoring programmes (PDMPs)

PDMPs (programs designed to track prescribing and dispensing of prescription drugs of potential extra-medical use) are being introduced in Australia, although their characteristics remain unclear, and there are likely to be jurisdictional differences, with potentially different outcomes. Differences may include whether the program is: voluntary vs. mandatory; monitors S8 opioids only vs. S8 opioids and benzodiazepines; fully automated vs. requires specific actions from the prescriber or pharmacist (e.g. requesting a record); and real-time vs. time-lagged.

International research on the impacts of PDMPs indicate mixed findings, with effectiveness varying according to programme features 9. For example, some US states with PDMPs report reductions in prescription opioid poisonings, with stronger protective effects where PDMPs monitored more schedules or required more regular reporting10. Less clear is how PDMPs will impact upon other aberrant behaviours (i.e., patient practices that are divergent from those ‘as directed’ by the prescriber5, such as use of opioid medicines for reasons other than pain, or use via unintended routes of administration), other substance use (prescribed or illicit), and opioid use disorders. Other unintended consequences have also been suggested, including stigmatisation of patients and a “chilling effect” where prescribers underuse opioids due to fear of repercussions, rapidly reduce opioid doses or cease opioids altogether, leading to inadequate pain relief or opioid withdrawal 11. Whilst PMPs have intrinsic face validity – in practice there remain many unanswered questions.

An alternative approach to establishing stand-alone PDMPs is the impending expansion of My Health Record (MHR). Many aspects of PDMPs can be incorporated into MHR, however the focus of MHR is to more broadly enhance co-ordination and quality of healthcare, efficiency and patient safety, rather than an emphasis upon medications only, as is the case of PDMPs. This is likely to be less stigmatising and offer better integration into routine healthcare than stand-alone PDMPs requiring their own infrastructure. There is concern among many groups about the manner in which this data could potentially be used, particularly in the criminal justice system. Medical and consumer groups will also need to consider how MHR will address S8 medications – the ability for a patient to ‘opt out’ – or for a doctor to require access to MHR prior to opioid prescribing beyond emergency presentations.

Reponses to minimise harmful patterns of use and harm

Abuse-deterrent formulations

Abuse-deterrent opioid formulations are intended to minimise extra-medical use by targeting use involving unintended routes of administration. Examples include making tablets tamper-resistant12 or including naloxone to deter injection13. In Australia, available evidence from convenience samples suggests most individuals tampering with pharmaceutical opioids take these drugs via injection, on an infrequent basis, and use a variety of pharmaceutical opioids and heroin14. Australian post-marketing surveillance studies show reductions in use and tampering amongst people who inject drugs following introduction of abuse-deterrent formulations, with no evidence of switching to other pharmaceutical opioids or heroin14 However, these formulations have not eradicated tampering and injection, and appear to have had limited impacts on overall opioid utilisation and population-level harm14. Unlike the Food and Drug Administration in the US, the Australian Therapeutic Goods Administration is yet to adopt an abuse-deterrent framework to enable the development and propagation of abuse-deterrent formulations over higher-risk opioid formulations.

Other responses to reduce pharmaceutical opioid-related harms

Greater availability of multidisciplinary pain services for people with CNCP and addiction treatment services for opioid dependent people are necessary to direct patients to more effective and safer treatment approaches than a reliance on opioid medications for CNCP. Screening for potential opioid problems is also important, with guidelines currently recommending that people with CNCP be assessed for such problems prior to initiating opioids15.

Access to multidisciplinary services

Contemporary guidelines regarding the management of CNCP emphasise the importance of multidisciplinary approaches that integrate medication, psychological approaches, and physical therapies. Many such services are most effectively and efficiently provided in  multi-disciplinary teams, however, few non-medical services are funded by Medicare in the community, and hence out-of-reach for the majority of patients requiring their assistance. There continues to be unmet capacity to deliver multi-disciplinary team approaches within state–funded Local Health Districts or private health services, and much more needs to be done to enhance access. The inability to access effective non-medication-based treatments likely contributes to an overreliance upon opioid medications. There is a need to integrate more addiction services into pain management programs. In a review of 57 pain management services in Australia, only four offered a combined pain and addiction service16. National benchmarks for quality and access to multidisciplinary care for patients suffering persistent pain are lacking. With the National Pain Strategy now back on the agenda, it is hoped that and recommendations to collaborate more with addiction medicines will be become a priority area.

Access to Opioid Substitution Therapy (OST)

Despite increasing concern about pharmaceutical opioid dependence in Australia, the number of patients (per population) in OST (methadone/buprenorphine) has remained static for more than 15 years4. In a recent Australian study, few patients with concurrent chronic pain and opioid dependence 17 reported lifetime enrolment in OST, with participant’s indicating significant stigma associated with OST. The study highlighted the need to better integrate primary health, specialist pain and specialist addiction services.

Both methadone and buprenorphine are effective in the treatment of pharmaceutical opioid use disorders 18,19. High dose buprenorphine/buprenorphine-naloxone is proving a useful approach for patients with chronic pain and opioid use disorder 20. Yet few Australian general practitioners – estimated at no more than 10% - prescribe methadone or buprenorphine/naloxone, despite the recent relaxation in training and credentialing requirements in most jurisdictions. Studies have identified a number of barriers to general practice participation, including feeling ill-equipped to deal with behavioural challenges21, workload concerns21,22, and a lack of accessible specialist support 21,22. Many of these concerns can lessened with improved workforce training and retention 21,23,24.  Concerted efforts are required to enhance the uptake of effective treatments by general practitioners, and address many of the perceived barriers.  Expansion of specialist addiction services will be required as PDMPs begin to identify patients with opioid use disorders (OUDs). 

Naloxone availability

Interest in the use of ‘take home naloxone’ (THN) as a strategy to reduce opioid overdose deaths has grown in recent years25, and supported by the World Health Organization. In Australia, THN programs are now incorporated in a range of services targeting people who inject drugs, including peer-based, needle and syringe programs, and Alcohol and other Drug (AoD) treatment services 25. However, THN programmes have been less widely established outside of these settings 25. Services targeting people with a history of injecting opioid use reach few CNCP patients, and efforts are required to engage doctors who prescribe opioids to also consider THN interventions for their patients.

Since 1st February 2016, naloxone was re-scheduled to Schedule 3, and is now available OTC, although there has been limited uptake and strategies are urgently needed to improve pharmacists’ knowledge and confidence in educating customers regarding opioid overdose and effective use of naloxone. Although previously only available as an injection, an intra-nasal formulation has recently been registered for use in Australia, which may improve its acceptability and attractiveness for use. However, whilst THN is important in reducing opioid-related overdoses, it is unlikely to impact on overall levels of opioid utilisation.

Education and advocacy for consumers and health care providers

In recent years, various government and non-government organisations have undertaken initiatives to promote education on the quality use of opioids and also an increasing awareness about opioid-related problems through various organisation-based websites and position statements. Examples include the NSW Agency for Clinical Innovation’s Pain Management Network which provides information for consumers and health professionals on the management of chronic pain. Scriptwise is a not-for-profit organisation that aims to prevent extra-medical use of prescription medications and overdose fatalities in Australia. Within the pain management sector, there has also been growing emphasis on the need to ‘deprescribe’ opioids and adopt multidisciplinary non-medication-based approaches to managing pain, as outlined in The Australian Pain Society’s Guiding Principles for Pain Management.

Actions for the future

It is important to reduce harms associated with pharmaceutical opioid use, but equally important that we do not prevent access for those who may benefit from opioid treatment. Our emphasis should be upon enhancing patient outcomes and safety – and recognise that regulatory responses such as rescheduling drugs, introducing PDMPs or abuse deterrent medicines are merely a means to achieve that end, and inadequate on their own. Notably, these responses are required to occur in an environment with many competing interests (e.g. industry vs government), which can be challenging. Overall, we need better education of health provider and consumers, better communication between providers through electronic clinical information systems, and increased availability of specialist pain and addiction services that work collaboratively with primary care providers.  We must address the stigma of addiction that prevents patients and their doctors from effectively addressing this issue – much in the same we have made inroads in countering the stigma of mental health problems in the community over the past two decades. As a society we need to reverse our over-reliance on medications as solutions for chronic health problems.

The vastness of the problem and the breadth of required approaches suggests we need to revisit the role of a national policy with clear targets, implementation and evaluation strategies – absent from the last National Framework.  Many of the solutions were identified a decade ago but have not been implemented. There are too many Australians experiencing opioid related harms for us to neglect this issue for another decade. 

This article first appeared in the Medial Journal of Australia. Campbell, G., Lintzeris, N., Gisev, N., Larance, B., Pearson, S., & Degenhardt, L. (2019). Regulatory and other responses to the pharmaceutical opioid problem. Medical Journal of Australia, 210(1), 6-8.e1. doi:10.5694/mja2.12047

References:

  1. Berterame S, Erthal J, Thomas J, et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet (London, England) 2016;387:1644-56.
  2. Karanges EA, Blanch B, Buckley NA, Pearson SA. Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims. British journal of clinical pharmacology 2016;82:255-67.
  3. Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annual review of public health 2015;36:559-74.
  4. Australian Institute of Health and Welfare. Non-medical use of pharmaceuticals: trends, harms and treatment, 2006-07 to 2015-16. In: Welfare AIoHa, ed. Canberra2017.
  5. Larance B, Degenhardt L, Lintzeris N, Winstock A, Mattick R. Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug and Alcohol Review 2011;30:236-45.
  6. National Pharmaceutical Drug Misuse Framework for Action (2012-2015). National Pharmaceutical Drug Misuse Framework for Action (2012-2015). 2012.
  7. Cairns R, Brown JA, Buckley NA. The impact of codeine re-scheduling on misuse: a retrospective review of calls to Australia's largest poisons centre. Addiction (Abingdon, England) 2016;111:1848-53.
  8. Schug SA, Dobbin MD, Pilgrim JL. Caution with the forthcoming rescheduling of over-the-counter codeine-containing analgesics. The Medical journal of Australia 2018;208:51-2.
  9. Fink DS, Schleimer JP, Sarvet A, et al. Association Between Prescription Drug Monitoring Programs and Nonfatal and Fatal Drug Overdoses. Ann Intern Med 2018;168:783-90.
  10. Pauly NJ, Slavova S, Delcher C, Freeman PR, Talbert J. Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings. Drug and Alcohol Dependence 2018;184:26-32.
  11. Islam MM, McRae IS. An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: pros, cons and tensions. BMC Pharmacology & Toxicology 2014;15:46-.
  12. Peacock A, Degenhardt L, Hordern A, et al. Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation. The International journal on drug policy 2015;26:1265-72.
  13. Larance B, Lintzeris N, Ali R, et al. The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug Alcohol Depend 2014;136:21-7.
  14. Larance B, Dobbins T, Peacock A, et al. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. The Lancet Psychiatry 2018.
  15. Therapeutic Guidelines. eTG Complete: Analgesic. Therapeutic Guidelines. In: Ltd. TG, ed. Melbourne, Australia2018.
  16. Hogg MN, Gibson S, Helou A, DeGabriele J, Farrell MJ. Waiting in pain: a systematic investigation into the provision of persistent pain services in Australia. Medical Journal of Australia 2012;196:386.
  17. Larance B, Campbell G, Moore T, et al. Concerns and Help-Seeking Among Patients Using Opioids for Management of Chronic Noncancer Pain. Pain Medicine 2018:pny078-pny.
  18. Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database of Systematic Reviews 2016;CD011117
  19. Nielsen S, Larance B, Lintzeris N. Opioid Agonist Treatment for Patients With Dependence on Prescription Opioids. JAMA 2017;317:967-8.
  20. Worley MJ, Heinzerling KG, Shoptaw S, Ling W. Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain. Experimental and clinical psychopharmacology 2015;23:428-35.
  21. Holliday S, Magin P, Oldmeadow C, et al. An examination of the influences on New South Wales general practitioners regarding the provision of opioid substitution therapy. Drug and Alcohol Review 2013;32:495-503.
  22. Scarborough J, Eliott J, Braunack-Mayer A. Opioid substitution therapy A study of GP participation in prescribing. Australian Family Physician 2011;40:241-5.
  23. Hotham E, Roche A, Skinner N, Dollman B. The general practitioner pharmacotherapy prescribing workforce: examining sustainability from a systems perspective. Drug and Alcohol Review 2005;24:393-400.
  24. Longman C, Lintzeris N, Temple-Smith M, Gilchrist G. Methadone and buprenorphine prescribing patterns of Victorian general practitioners: Their first 5 years after authorisation. Drug and Alcohol Review 2011;30:355-9.
  25. Dwyer R, Olsen A, Fowlie C, et al. An overview of take‐home naloxone programs in Australia. Drug and alcohol review 2018;37:440-9.